drugset / Trial / NCT05066373

Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

NCT05066373

Phase 1 Completed 48 enrolled Evelo Biosciences, Inc.
Non-randomizedCrossoverOpen-labelOther

Summary

This study is to find out how different types of capsules or tablets containing EDP1815 move through the GI tract and release the drug after being swallowed. The capsules and tablets also contain a very small dose of a commonly used radioactive label called technetium-99m which is released in the GI tract to be seen on pictures taken by a scanner (gamma scintigraphy).

Timeline

Start
2021-08-09
Primary completion
2022-08-11
Completion
2022-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP1815 Other / unclassified Oral

Indications

No indication recorded.